ADVM Adverum Biotechnologies, Inc.

2.73
-0.075  -3%
Previous Close 2.80
Open 2.75
Price To book 0.60
Market Cap 116.82M
Shares 42,869,000
Volume 113,446
Short Ratio 2.87
Av. Daily Volume 229,800

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
ADVM-043
Alpha-1 Antitrypsin (A1AT) Deficiency
Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
AVA-101
Wet age-related macular degeneration (Wet-AMD)

Latest News

  1. Adverum Biotechnologies to Present at the Jefferies Global Healthcare Conference
  2. ETFs with exposure to Adverum Biotechnologies, Inc. : May 15, 2017
  3. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  4. Adverum Biotechnologies, Inc. Announces Data Presentations at the ARVO and ASGCT 2017 Annual Meetings
  5. Adverum Biotechnologies posts 1Q loss
  6. Adverum Biotechnologies Reports First Quarter 2017 Financial Results and Provides Update
  7. What's in Store for Adverum (ADVM) in Q1 Earnings?
  8. Adverum Biotechnologies, Inc. Appoints Richard N. Spivey, Pharm.D., Ph.D. to Board of Directors
  9. Adverum Biotechnologies Announces Updated Presentation Time for ARM 5th Annual Cell & Gene Therapy Investor Day
  10. ETFs with exposure to Adverum Biotechnologies, Inc. : April 12, 2017
  11. Adverum Biotechnologies to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
  12. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  13. Adverum Biotechnologies, Inc. :ADVM-US: Earnings Analysis: 2016 By the Numbers : March 15, 2017
  14. Adverum Biotechnologies, Inc. Appoints Patrick Machado, J.D. to Board of Directors
  15. Adverum Biotechnologies Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Update
  16. Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
  17. Is KCAP Financial Inc (KCAP) A Good Stock to Buy?